Catalog No.
KDB94402
Stability and Storage
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Detection method
Colorimetric
Precision
CV<20%
Sample type
Plasma, Serum
Assay type
Quantitative
Sensitivity
0.156 μg/ml
Range
0.31-5 μg/mL
Recovery
80-120%
Specifications
Certolizumab
Alternative Names
CDP870, PHA-738144, Certolizumab pegol, CAS: 428863-50-7
Background
Certolizumab pegol is a recombinant, humanized F(ab)’ fragment of an antibody conjugated to polyethylene glycol to enhance its plasma half-life. It does not contain an FC region and therefore does not cause antibody-dependent cell-mediated or complement-dependent cytotoxicity as described for infliximab, etanercept, and adalimumab. Another difference is that certolizumab pegol preferentially penetrates inflamed tissue compared to noninflamed tissue, and does so to a greater extent than adalimumab or infliximab. It is directed against soluble and membrane-associated human TNF-α and was approved for the treatment of Crohn’s disease that does not respond to conventional therapy in 2008 and for RA in 2009.
Shipping
2-8 ℃
Note
For Research Use Only.
For research use only. Not for human or drug use.
